VTRS Stock - Viatris Inc.
Unlock GoAI Insights for VTRS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $14.74B | $15.43B | $16.26B | $17.89B | $11.95B |
| Gross Profit | $5.62B | $6.44B | $6.50B | $5.58B | $3.80B |
| Gross Margin | 38.2% | 41.7% | 40.0% | 31.2% | 31.8% |
| Operating Income | $10.10M | $766.20M | $1.61B | $-34,000,000 | $-210,800,000 |
| Net Income | $-634,200,000 | $54.70M | $2.08B | $-1,269,100,000 | $-669,900,000 |
| Net Margin | -4.3% | 0.4% | 12.8% | -7.1% | -5.6% |
| EPS | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 |
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $15 |
| October 15th 2025 | Truist | Initiation | Buy | $15 |
| June 6th 2025 | Goldman | Initiation | Neutral | $10 |
| July 19th 2024 | Jefferies | Resumed | Buy | $15 |
| October 23rd 2023 | BofA Securities | Downgrade | Underperform | $9← $13 |
| June 23rd 2023 | Barclays | Downgrade | Underweight | $11 |
| April 24th 2023 | Barclays | Downgrade | Equal Weight | $11 |
| February 17th 2023 | BMO Capital Markets | Downgrade | Market Perform | $14← $16 |
| January 27th 2023 | Jefferies | Upgrade | Buy | $15← $13 |
| November 10th 2022 | UBS | Upgrade | Neutral | $12← $9 |
| November 8th 2022 | Piper Sandler | Upgrade | Neutral | $10 |
| October 21st 2022 | Jefferies | Resumed | Hold | $11 |
| June 14th 2022 | UBS | Initiation | Sell | $9 |
| May 10th 2022 | Piper Sandler | Downgrade | Underweight | $10 |
Earnings History & Surprises
VTRSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.53 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.62 | $0.67 | +7.9% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $0.56 | $0.62 | +11.5% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.49 | $0.50 | +1.6% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $0.61 | $0.54 | -11.5% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $0.68 | $0.75 | +10.8% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $0.68 | $0.69 | +1.8% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $0.67 | $0.67 | -0.4% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $0.67 | $0.61 | -9.0% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $0.74 | $0.78 | +5.4% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $0.71 | $0.75 | +5.6% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $0.69 | $0.78 | +13.0% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $0.72 | $0.67 | -6.9% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $0.82 | $0.86 | +4.9% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $0.81 | $0.88 | +8.6% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $0.81 | $0.93 | +14.8% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $0.82 | $0.80 | -2.4% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $0.86 | $0.99 | +15.1% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $0.88 | $0.98 | +11.4% | ✓ BEAT |
Latest News
Trump Administration Proposes Rule Banning Medicaid And CHIP From Paying For Gender Affirming Care
➖ NeutralViatris Secures Four Global Regulatory Milestones With FDA Approval Of Octreotide, NDA Review For Estrogen Patch, IND Clearance For MR‑146 Gene Therapy, And PMDA Acceptance Of Pitolisant
📈 PositiveBarclays Initiates Coverage On Viatris with Overweight Rating, Announces Price Target of $15
📈 PositiveReported Saturday, Viatris Enters Definitive Agreements With Biocon To Sell Biocon Biologics Convertible Preferred Equity For Total Consideration Of $815M
📈 PositiveViatris shares are trading lower after the company reported Q3 financial results.
📉 NegativeViatris Raises FY2025 Adj EPS Guidance from $2.16-$2.30 to $2.25-$2.35 vs $2.29 Est; Raises FY2025 Sales Guidance from $13.500B-$14.000B to $13.900B-$14.300B vs $13.928B Est
📈 PositiveViatris Q3 Adj. EPS $0.67 Beats $0.62 Estimate, Sales $3.759B Beat $3.609B Estimate
📈 PositiveViatris And Locus Biosciences Enter Research Collaboration To Develop Precision Antibacterial Therapies For Ophthalmic Infections
📈 PositiveTruist Securities Initiates Coverage On Viatris with Buy Rating, Announces Price Target of $15
📈 PositiveViatris shares break six-session winning streak
📉 NegativeViatris rises after a steep seven-day slide
📈 PositiveMapi Pharma Enrolls First Patient Into Phase I/II Study Evaluating Cariprazine Once Monthly Injection
📈 PositiveFDA Announces Discontinuation Of Manufacture Of DYMISTA Nasal Spray, 137 mcg; 50 mcg A Registered Trademark Of Meda Pharmaceuticals Inc., A Viatris Company
📉 NegativeTheravance higher as China approves Viatris-partnered COPD therapy
📈 PositiveViatris on track to close seventh straight session of gains
📈 PositiveFrequently Asked Questions about VTRS
What is VTRS's current stock price?
What is the analyst price target for VTRS?
What sector is Viatris Inc. in?
What is VTRS's market cap?
Does VTRS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VTRS for comparison